Lakefront Biotherapeutics NV (FRA:GXEA)

Market Cap	1.62B -8.8%
Revenue (ttm)	990.57M +259.4%
Net Income	596.64M
EPS	9.05
Shares Out	n/a
PE Ratio	2.72
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	25.00
Previous Close	24.00
Day's Range	25.00 - 25.00
52-Week Range	22.40 - 31.40
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2026

About FRA:GXEA

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relaps...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 196
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: GXEA

Financial Performance

In 2025, FRA:GXEA's revenue was 1.11 billion, an increase of 303.50% compared to the previous year's 275.65 million. Earnings were 320.88 million, an increase of 333.15%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 19, 2026

Data Sources Report a data error